tumor tissues; paired adjacent normal tissues; tumor tissues and lung tissues
MCF10A; BT549; HCC38; MDA-MB-453; MDA-MB-468; MDA-MB-231
cell line-derived xenograft
proliferation (promotes); migration (promotes); invasion (promotes); EMT (promotes); mRNA stability (promotes); other pathway/process (promotes)
RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Actinomycin D / DRB Stability Assay; Transfection; CCK8; EdU Staining; Transwell Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model
May provide a potential therapeutic target for TNBC treatment.
circKIF4A is up-regulated in TNBC tissues and cell lines and acts as an oncogenic circRNA. It binds EIF4A3 to stabilize SDC1 mRNA, thereby increasing SDC1 expression and activating c-src/FAK signaling to promote TNBC cell proliferation, migration, invasion, EMT-related changes, and xenograft tumor growth.
0.8252
CircKIF4A combines EIF4A3 to stabilize SDC1 expression to activate c-src/FAK and promotes TNBC progression.
combined biological and clinical study